CTOs on the Move

Atrium Innovations

www.atrium-innovations.com

 
Atrium Innovations is recognized around the world as an innovative leader in the development, manufacturing, and commercialization of science-based nutritional health products.
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.atrium-innovations.com
  • Place Alexis Nihon – Tower 2 – 24th floor 3500 de Maisonneuve Boulevard West, suite 2405
    Westmount, QC CAN H3Z 3C1
  • Phone: 514.205.6240

Executives

Name Title Contact Details

Similar Companies

Citrus Health Care

Citrus Health Care is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Patient-Centered Outcomes Research Institute

Patient-Centered Outcomes Research Institute is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wilderness Adventure At Eagle

Wilderness Adventure At Eagle is a New Castle, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cary HealthCare L L C

Cary HealthCare L L C is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic